No incontinence and no negative change in erectile function in prostate cancer patients with recurrent disease
Can patients with returning prostate cancer get treatment without fear of incontinence and erectile dysfunction? A novel study shows they can: The Vitus Prostate Center presented data on recurrent disease at the Annual Meeting of the Radiological Society of North America (RSNA) in Chicago.
The data showed results of the treatment of 40 patients by means of NanoKnife who had recurrent prostate cancer. Patients had previously been treated with prostatectomy, radiation therapy and HIFU, amongst other pre-treatments. The study reveals the high feasibility even after surgical removal of the prostate, overall low side effect rates as well as astonishing functional outcome on potency and continence. With merely 6 patients experiencing recurrent disease at a maximum follow-up time of 51 months, the results also show good oncological outcome for this subgroup of high-risk patients.
Read here a commented summary of the data which was presented at the 2017 Annual Meeting of the Radiological Society of North America:
The Radiological Society of North America (RSNA) is an international society of radiologists, medical physicists and other medical professionals with more than 54,000 members across the globe. RSNA hosts one of the world’s largest annual medical meetings. Dr. Stehling and his team have presented at the RSNA for several years in a row now.